Ferroptosis is a form of regulated cell death triggered by lipid peroxidation after inhibition of the cystine/ glutamate antiporter system X c -. However, key regulators of system X c -activity in ferroptosis remain undefined. Here, we show that BECN1 plays a hitherto unsuspected role in promoting ferroptosis through directly blocking system Xc -activity via binding to its core component, SLC7A11 (solute carrier family 7 member 11). Knockdown of BECN1 by shRNA inhibits ferroptosis induced by system X c -inhibitors (e.g., erastin, sulfasalazine, and sorafenib), but not other ferroptosis inducers including RSL3, FIN56, and buthionine sulfoximine. Mechanistically, AMPactivated protein kinase (AMPK)-mediated phosphorylation of BECN1 at Ser90/93/96 is required for BECN1-SLC7A11 complex formation and lipid peroxidation. Inhibition of PRKAA/AMPKa by siRNA or compound C diminishes erastin-induced BECN1 phosphorylation at S93/96, BECN1-SLC7A11 complex formation, and subsequent ferroptosis. Accordingly, a BECN1 phosphorylation-defective mutant (S90,93,96A) reverses BECN1-induced lipid peroxidation and ferroptosis. Importantly, genetic and pharmacological activation of the BECN1 pathway by overexpression of the protein in tumor cells or by administration of the BECN1 activator peptide Tat-beclin 1, respectively, increases ferroptotic cancer cell death (but not apoptosis and necroptosis) in vitro and in vivo in subcutaneous and orthotopic tumor mouse models. Collectively, our work reveals that BECN1 plays a novel role in lipid peroxidation that could be exploited to improve anticancer therapy by the induction of ferroptosis.
In Brief
Song et al. find that BECN1 promotes ferroptosis by directly blocking system Xc -activity via binding to its core component SLC7A11. This pathway is different from the previously identified function of BECN1 as a positive regulator of autophagy via directly activating PtdIns3K activity via binding to its core component PIK3C3.
SUMMARY
Ferroptosis is a form of regulated cell death triggered by lipid peroxidation after inhibition of the cystine/ glutamate antiporter system X c -. However, key regulators of system X c -activity in ferroptosis remain undefined. Here, we show that BECN1 plays a hitherto unsuspected role in promoting ferroptosis through directly blocking system Xc -activity via binding to its core component, SLC7A11 (solute carrier family 7 member 11). Knockdown of BECN1 by shRNA inhibits ferroptosis induced by system X c -inhibitors (e.g., erastin, sulfasalazine, and sorafenib), but not other ferroptosis inducers including RSL3, FIN56, and buthionine sulfoximine. Mechanistically, AMPactivated protein kinase (AMPK)-mediated phosphorylation of BECN1 at Ser90/93/96 is required for BECN1-SLC7A11 complex formation and lipid peroxidation. Inhibition of PRKAA/AMPKa by siRNA or compound C diminishes erastin-induced BECN1 phosphorylation at S93/96, BECN1-SLC7A11 complex formation, and subsequent ferroptosis. Accordingly, a BECN1 phosphorylation-defective mutant (S90,93,96A) reverses BECN1-induced lipid peroxidation and ferroptosis. Importantly, genetic and pharmacological activation of the BECN1 pathway by overexpression of the protein in tumor cells or by administration of the BECN1 activator peptide Tat-beclin 1, respectively, increases ferroptotic cancer cell death (but not apoptosis and necroptosis) in vitro and in vivo in subcutaneous and orthotopic tumor mouse models. Collectively, our work reveals that BECN1 plays a novel role in lipid peroxidation that could be exploited to improve anticancer therapy by the induction of ferroptosis.
INTRODUCTION
System X c -is a heterodimeric cystine/glutamate antiporter and is composed of two core components: SLC7A11 (solute carrier family 7 member 11; the catalytic subunit) and SLC3A2 (solute carrier family 3 member 2; an anchoring protein). This amino acid antiporter plays a role in maintaining an intracellular reducing environment by importing cystine, which is reduced to cysteine and then used to synthesize the major antioxidant glutathione (GSH). Impairment of the system X c --dependent antioxidant defense system results in oxidative injury and cell death. In particular, pharmacological inhibition of system X c -activity by certain small-molecule compounds or drugs (e.g., erastin, sulfasalazine, and sorafenib) can trigger ferroptosis, a lipid-peroxidation-dependent form of non-apoptotic regulated cell death [1] [2] [3] . However, key regulators of system X c -activity in ferroptosis remain undefined.
BECN1 (beclin 1) is a key player of macroautophagy/autophagy because it is the central constituent of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex [4, 5] . In addition to binding to core components or regulators of the PtdIns3K complex (e.g., PIK3C3 [phosphatidylinositol 3-kinase catalytic subunit type 3], ATG14 [autophagy related 14] , and UVRAG [UV radiation resistance associated]), BECN1 can interact with additional protein partners to regulate various cell processes (e.g., endocytosis and phagocytosis) in both autophagy-dependent and -independent manners [6] [7] [8] . To uncover the pleiotropic function of BECN1, it is important to explore the stress-induced changes in the composition of the BECN1 interactome, as well as the post-translational modifications (PTMs) occurring within distinct BECN1 complexes.
Here, we report that BECN1 plays a non-autophagic role in promoting ferroptosis by binding to SLC7A11. Notably, AMPactivated protein kinase (AMPK)-mediated phosphorylation of BECN1 at Ser90/93/96 is required for BECN1-SLC7A11 complex formation and subsequent lipid peroxidation in ferroptosis. Thus, BECN1 contributes to the core molecular machinery and signaling pathways involved in ferroptosis. 
RESULTS

BECN1
Is Required for System X c --Inhibitor-Induced Ferroptosis To determine the role of BECN1 in ferroptosis, BECN1 protein expression was measured in human cancer cell lines including HCT116 (colon adenocarcinoma), CX-1 (colon adenocarcinoma), PANC1 (pancreatic ductal adenocarcinoma), HT1080 (fibrosarcoma), and Calu-1 (non-small-cell lung cancer) cells. Consistent with previous studies showing that ferroptosis is associated with increased autophagy [9, 10] , erastin (a classical inducer of ferroptosis) induced the conversion of the autophagic marker MAP1LC3B (microtubule associated protein 1 light chain 3 beta)-I to -II, as determined by immunoblot analysis ( Figure 1A ) and increased the formation of MAP1LC3B puncta formation, as determined by immunofluorescence staining and image analysis (Figures S1A and S1B). Normal cell-culture condition did not induce MAP1LC3B-II expression in PANC1 and Calu-1 cells after 24-hr culture ( Figure S1C ). In addition to erastin-induced BECN1 expression in HT1080 cells, there were no significant changes in the protein expression of BECN1 in other cell lines ( Figure 1A ), indicating that the inducible expression of BECN1 may not be essential for erastin-induced autophagosome formation.
Next, we investigated the possibility that the expression of BECN1 might affect the anticancer activity of system X c -inhibitors (e.g., erastin, sulfasalazine, and sorafenib) in HCT116, CX-1, and HT1080 cells. Transfection-enforced overexpression of BECN1 ( Figure 1B ) sensitized cancer cells to system X c --inhibitor-induced death ( Figure 1C) . Conversely, depletion of BECN1 by short hairpin RNA (shRNA)-mediated RNA interference ( Figure 1D ) conferred resistance to system X c -inhibitors ( Figure 1E ). Moreover, knockdown of BECN1 by means of two additional, non-overlapping shRNAs ( Figure S2A ) inhibited cell death induced by erastin, sulfasalazine, and sorafenib in HCT116 and HT1080 cells ( Figure S2B ). Propidium iodide staining confirmed that knockdown of BECN1 inhibited erastin and sulfasalazine-induced cell death in HT1080 cells ( Figure S2C ). In contrast, alterations of BECN1 expression did not affect cell death induced by other ferroptosis inducers including GPX4 (glutathione peroxidase 4) inhibitor (RSL3 and FIN56) and GSH synthase inhibitor (buthionine sulfoximine [BSO]) ( Figures 1C, 1E , and S2B). Of note, knockdown of BECN2 (a paralog of BECN1 [11] ) by small interfering RNA (siRNA) ( Figure 1F ) did not change the anticancer activity of erastin, sulfasalazine, and sorafenib ( Figure 1G ) in HeLa cells. Thus, the expression of BECN1 selectively contributes to the anticancer activity of those ferroptosis inducers that target system X c -, but not those that act downstream of system X c -.
Given that BECN1 is also involved in the regulation of apoptosis and other types of regulated cell death [6] , we explored the possibility that these forms of regulated cell death might contribute to the anticancer activity of erastin in BECN1-overexpressing cells. To evaluate this hypothesis, we used various cell death inhibitors. Ferroptosis inhibitors (ferrostatin-1 and liproxstatin-1) restored cell viability in BECN1-overexpressing cells (HCT116, CX-1, and HT1080) cultured with X c -inhibitors ( Figure S2D ). In contrast, Z-VAD-FMK (an apoptosis inhibitor) or necrosulfonamide (a necroptosis inhibitor) ( Figure S2D ) failed to improve cellular viability in these circumstances. As an internal control, Z-VAD-FMK (but not ferrostatin-1 and liproxstatin-1) inhibited cell death induced by the pro-apoptotic agent staurosporine ( Figure S2E ), and necrosulfonamide (but not ferrostatin-1) inhibited necroptosis induction by TZC (a combination of TNF [tumor necrosis factor], Z-VAD-FMK, and cycloheximide) ( Figure S2F ). Collectively, these findings indicate that BECN1 is required for system X c --inhibitor-induced ferroptosis.
BECN1 Promotes GSH Depletion and Lipid Peroxidation in Ferroptosis
Although the function of BECN1 in autophagosome formation is established, several studies have revealed various non-autophagic functions of BECN1 [8] . To distinguish between the autophagy-dependent and -independent roles of BECN1 in ferroptosis, we measured the lipidation and subcellular distribution of MAP1LC3B in BECN1-overexpressing, BECN1-depleted, and control cells in the absence or presence of erastin. Alterations in BECN1 expression did not affect the erastin-induced formation of lipidated MAP1LC3B (i.e., the generation of MAP1LC3B-II, leading to an increase in its electrophoretic mobility) ( Figure 2A ) and MAP1LC3B-positive puncta ( Figure S4 Figure S3C ) inhibited system X c -inhibitor (erastin, sulfasalazine, and sorafenib)-induced cell death ( Figure S3D ) associated with decreased MAP1LC3B puncta formation ( Figure S3E ). These findings indicate that system X c --inhibitor-induced MAP1LC3B lipidation requires ATG5 but not BECN1.
Because lipid peroxidation is a critical driver of ferroptosis [1, 2] , we next hypothesized that BECN1-mediated ferroptosis is associated with increased lipid peroxidation. Erastin-or sulfasalazine-induced lipid peroxidation, assessed by means of the fluorescent biosensor C11-BODIPY or by quantifying the oxidative stress marker malondialdehyde (MDA), was increased after overexpression of BECN1, but decreased after knockdown of BECN1 in HCT116 ( Figure 2C ), CX-1 ( Figure S3F ), and HT1080 cells ( Figure S3G ). In contrast, erastin-or sulfasalazine-induced accumulation of Fe
2+
, assessed by means of the Iron Assay Kit, was not significantly affected by BECN1 expression (Figures 2C, S3F, and S3G). Intracellular chelatable iron was further determined using the fluorescent indicator Phen Green SK, the fluorescence of which is quenched by iron [12] . Erastin-induced downregulation of the proportion of Phen Green SK-positive cells was not affected by knockdown of BECN1 in HT1080 cells ( Figure 2D) Figure 2E ). These findings suggest that BECN1 promotes system X c --inhibitor-induced ferroptosis through upregulation of lipid peroxidation, but not iron accumulation.
Given that GSH levels inversely correlate with lipid peroxidation [13] , we hypothesized that the increased lipid peroxidation in BECN1-overexpressing cancer cells should be associated with reduced GSH levels in ferroptosis. Indeed, overexpression of BECN1 increased GSH depletion, whereas depletion of BECN1 restored GSH levels in HCT116 ( Figure 2C ), CX-1 ( Figure S3F ), and HT1080 ( Figure S3G ) cells following erastin or sulfasalazine treatment. Moreover, the administration of GSH inhibited erastin-or sulfasalazine-induced death with increased intracellular GSH levels in wild-type and BECN1-overexpressing HCT116 cells ( Figure 2F ). These findings indicate that BECN1 promotes GSH depletion and lipid peroxidation in system X c --inhibitor-induced ferroptosis.
BECN1 Inhibits System Xc -Activity through Direct Binding to SLC7A11
Previous studies have demonstrated that erastin not only inhibits system Xc -activity to trigger ferroptosis, but also upregulates the expression of SLC7A11 (the catalytic subunit of system Xc -) as a negative feedback loop to limit lipid peroxidation [3, 14] . We therefore investigated whether BECN1 alters the expression and activity of system Xc -to modulate GSH level and ferroptosis. BECN1 expression did not affect the erastininduced SLC7A11 mRNA upregulation in HCT116 and CX-1 cells ( Figure S4A ). In contrast, a glutamate release assay indicated that the activity of system Xc -was inhibited in BECN1-overexpressing cells, whereas it was increased in BECN1-knockdown HCT116 and CX-1 cells following erastin treatment ( Figure 3A) . 
(legend continued on next page)
These findings suggest that BECN1 inhibits system Xc -activity, but not SLC7A11 expression.
Because BECN1 serves as a protein interaction platform [6] [7] [8] , we next asked whether BECN1 inhibits system Xc -activity through direct protein-protein interactions. Immunoprecipitation (IP) of cellular lysates by means of an anti-BECN1 or anti-SLC7A11 antibody followed by immunoblot detection of SLC7A11 or BECN1 revealed a significant BECN1-SLC7A11 interaction in HCT116 and/or CX-1 cells following erastin treatment ( Figure 3B ). Moreover, the erastin-induced BECN1-SLC7A11 complex was more abundant in BECN1-overexpressing HCT116 and CX-1 cells ( Figure 3B ). A similar phenomenon was further confirmed by IP assay using an anti-HA tag antibody in HCT116 and CX-1 cells expressed HA-BECN1 ( Figure 3C ). The formation of a BECN1-SLC7A11 complex also occurred in PANC1, HT1080, and Calu-1 cells following erastin or sulfasalazine treatment ( Figure 3D ). An image assay showed that the colocalization between BECN1 and SLC7A11 occurs mostly in the cytoplasm in CX-1 cells following erastin treatment ( Figure 3E ). Moreover, the BECN1 activator peptide Tat-beclin 1 (H 2 N-YGRKKRRQRRR-GG-TNVFNATFEIWHDGEFGT-CO 2 H) [15] increased BECN1-SLC7A11 complex formation ( Figure 3F ), the inhibition of glutamate release ( Figure 3G ), and subsequent cell death in HCT116 cells following erastin or sulfasalazine treatment ( Figure 3H ). These findings indicate that the formation of the BECN1-SLC7A11 complex inhibits system Xc -activity in ferroptosis.
Of note, the increased BECN1-SLC7A11 complex was not observed in starvation (HBSS)-induced autophagy ( Figure S4B ), although starvation did induce formation of the BECN1-PIK3C3 complex, as expected [6] . However, erastin did not induce the BECN1-PIK3C3 interaction ( Figure S4B ). These observations suggest that SLC7A11 and PIK3C3 form mutually exclusive complexes with BECN1 in the context of ferroptosis and classical autophagy, respectively.
BECN1 Phosphorylation at S90/93/96 Contributes to BECN1-SLC7A11 Complex Formation
Human BECN1 has 450 amino acids (aa), including three domains: a BH3 domain at the N terminus, a central coiled-coil domain (CCD), and a C-terminal half encompassing the evolutionarily conserved domain (ECD) that is present within the BARA domain [6] . To define the portions of the BECN1 protein responsible for the interaction with SLC7A11, we constructed a series of vectors that express fragments of BECN1 (1-150, 1-242, 151-241, and 243-450). IP assays showed that the aa 1-150 fragment of BECN1 can bind to SLC7A11 ( Figure 4A ). Compared to full-length BECN1, functional assays further demonstrated that aa 1-150 of BECN1 had the same ability to enhance erastin-or sulfasalazine-induced cell death and to concomitantly increase MDA production and deplete GSH ( Figure 4B ). In contrast, aa 243-450 of BECN1 failed to enhance erastin-or sulfasalazine-induced cell death and lipid peroxidation ( Figure 4B ). The BECN1 interactome is profoundly influenced through BECN1 phosphorylation by various kinases [16] . We therefore mutated putative phosphorylation sites in BECN1 by replacing serine (S) or threonine (T) residues to alanine (A) in aa 1-150 (S15A, S30A, S90A, T108A, T119A, and S90,93,96A). Moreover, we specifically deleted the BH3 domain (D114-128), knowing that this domain is important for inhibitory interactions with BCL2 and BCL2L1 [17] . IP assays showed that only the S90,93,96A mutant (but not any other Ser/Thr mutants nor the BH3 domain deletion) attenuated the interaction with SLC7A11 in erastin-induced ferroptosis ( Figure 4C ). Moreover, in contrast to full-length BECN1 and other phosphorylation mutants, the S90,93,96A mutant failed to enhance erastin-or sulfasalazineinduced cell death, MDA production, and GSH depletion (Figure 4D ). Iron accumulation was not affected by any of these phosphorylation mutants ( Figure 4D ). Collectively, these findings demonstrate that the phosphorylation of BECN1 at S90/93/96 contributes to BECN1-SLC7A11 complex formation and subsequent lipid peroxidation in ferroptosis.
AMPK Is Required for BECN1 Phosphorylation in Ferroptosis
It has been reported that AMP-activated protein kinase (AMPK) phosphorylates BECN1 at S90 and S93 to regulate autophagy or cell trafficking [18] . Erastin time-dependently increased BECN1 phosphorylation at S90 and S93, as well as the activating PRKAA/AMPKa phosphorylation at Thr172 in HCT116 and CX-1 cells ( Figure 5A ). To establish a direct link between PRKAA/ AMPKa and BECN1, we next sought to clarify whether inhibition of PRKAA/AMPKa expression or activity might suppress BECN1 phosphorylation and BECN1-SLC7A11 complex formation in ferroptosis. Genetic or pharmacological inhibition of PRKAA/ AMPKa by siRNA or by compound C, respectively, diminished erastin-induced BECN1 phosphorylation at S93/96 (Figures 5B and 5C) as well as BECN1-SLC7A11 complex formation ( Figures  5D and 5E ) in HCT116 and CX-1 cells. Pharmacological application of compound C may result in both AMPK-dependent and -independent effects in different contexts [19] . Similar to previous studies [3, 14] , erastin increased SLC7A11 expression (Figure 5D ). Unlike knockdown of PRKAA/AMPKa ( Figure 5D ), compound C increased SLC7A11 expression in HCT116 cells ( Figure 5E ), indicating that AMPK-independent effects of compound C regulate SLC7A11 expression. Consequently, knockdown of PRKAA/AMPKa or administration of compound C (Figures 5F and 5G) suppressed erastin-or sulfasalazine-induced death with decreased MDA production and increased GSH levels in HCT116 (Figures 5F and 5G) and CX-1 cells ( Figure S5 ). Again, iron accumulation was not changed by the genetic and pharmacological inhibition of AMPK ( Figures 5F, 5G, and S5) . Collectively, these findings support the hypothesis that PRKAA/AMPKa-mediated BECN1 phosphorylation promotes BECN1-SLC7A11 complex formation and subsequent lipid peroxidation in ferroptosis. (but not control) CX-1 cells ( Figure S6 ). In contrast, overexpression of BECN1 did not change the protein levels of cleaved CASP3/caspase 3 (a marker of apoptosis) and phosphorylation of MLKL (mixed lineage kinase domain like pseudokinase, a marker of necroptosis) with or without erastin treatment in vivo ( Figure 6E ). These data indicate that BECN1 expression sensitizes to erastin-induced lipid peroxidation, ferroptosis, and tumor suppression in vivo. We next investigated whether the BECN1 activator peptide Tat-beclin 1 enhances the anticancer activity of erastin in mouse tumor models. Tat-beclin 1 increased the anticancer activity of erastin in immunodeficient nude mice after subcutaneous implantation of HCT116 or HT1080 cells ( Figure 6F ). Like overexpression of BECN1 ( Figure 6E ), administration of Tat-beclin 1 did not change the protein levels of cleaved CASP3 and phosphorylation of MLKL with or without erastin treatment in vivo ( Figure 6G ). Furthermore, Tat-beclin 1 combined with erastin was more efficient than erastin alone in increasing animal survival in an orthotopic pancreas cancer (Pdx1-Cre;K-Ras
G12D/+ ;Trp53
R172H/+ or KPC) model (Figure 6H ). Liproxstatin-1 (an inhibitor of ferroptosis) blocked the anticancer activity of erastin combined with Tat-beclin 1 in these animal models (Figures 6F and 6H) . Altogether, these results further support the idea that activation of the BECN1 pathway effectively enhances the anticancer activity of erastin by induction of ferroptosis, but not apoptosis or necroptosis.
DISCUSSION
In this study, we reported that BECN1 plays a new role in the control of system Xc -activity, which is critical for ferroptosis The term ''ferroptosis'' was first coined in 2012 and was largely based on the observation of an iron-dependent form of nonapoptotic cell death in cancer cells triggered by erastin [3] . In addition to its potential utility in cancer therapy [20] [21] [22] [23] [24] [25] [26] [27] , ferroptosis may represent an inflammatory cell death involved in tissue injury and immune regulation [28] [29] [30] [31] [32] [33] . The mechanism of erastininduced ferroptosis is still not fully understood at the molecular level, although it is well known that it requires the RAS-RAF-MAP2K/MEK-MAPK/ERK signaling cascade and is highly cell specific [34] . In recent years, accumulating evidence indicates that lipid peroxidation plays a central role in the initiation and progression of ferroptosis. In particular, pharmacological inhibition of system Xc -leads to lipid peroxidation and ferroptosis [35] . Our results indicate that the system Xc -inhibitors erastin or sulfasalazine promote BECN1 binding to SLC7A11 as an early step to initiate ferroptosis. This negative feedback step seems to be an important regulatory mechanism for limiting system Xc -activity following the upregulation of SLC7A11 expression. Inhibition of SLC7A11 expression at the transcriptional level is an alternative strategy to inhibit system Xc -activity and consequently enhance ferroptosis [14, 36] . Thus, there are least two modes, transcription independent (protein-protein interaction) and transcription dependent, for the control of system Xc -activity in ferroptosis.
A rich collection of literature has demonstrated the critical tie between autophagy, survival, and cell death, but why, how, and when autophagy switches from pro-survival to lethal functions is still under debate [37] [38] [39] . Autophagy involves dynamic and complicated processes and can occur using multiple variant mechanisms dependent or independent of core ATG proteins. Our current study indicates that BECN1-independent autophagy positively regulates system Xc --inhibitor-induced, but not GPX4-inhibitor-induced ferroptosis. Similarly, BECN1 is not required for apoptosis induction (e.g., by staurosporine, gossypol, and resveratrol) or for cis-unsaturated fatty-acid-induced autophagy in certain cancer cells [40, 41] .
Dynamic changes in the BECN1 interactome play a major role in the crosstalk between cell death and autophagy regulatory pathways. As a central platform of this interaction hub, BECN1 may affect a lethal signal transduction pathway through autophagy-dependent and independent mechanisms [6] [7] [8] .
Contrasting with the central pro-autophagic BECN1 function, which includes the interaction with PIK3C3 to form class III PtdIns3K complex, we demonstrated here that BECN1 promotes ferroptosis through interaction with SLC7A11. The structural basis of the regulation of the formation of different BECN1 complexes has partially been elucidated. For example, the BH3 domain of BECN1 mediates binding to BCL2 family proteins such as BCL2 itself and BCL2L1, the CCD domain interacts with UVRAG, and the ECD domain contributes to interaction with lipid membranes [42] [43] [44] . Our experimental evidence shows that aa 1-150 of BECN1 is required for BECN1-SLC7A11 formation in ferroptosis. Moreover, phosphorylation of BECN1 at S90/93/96 by AMPK increases binding to SLC7A11, meaning that AMPK inhibition and mutation of S90/ 93/96 to render these residues non-phosphorylable compromised the pro-ferroptotic function of BECN1. Of note, AMPKmediated BECN1 phosphorylation at T388 promotes BECN1-PIK3C3 complex formation in autophagy [45] . At present, however, we do not understand which additional signals acting on BECN1 (beyond AMPK activation) determine whether the protein will preferentially engage in BECN1-SLC7A11 or BECN1-PIK3C3 complexes to stimulate ferroptosis and autophagy, respectively.
It is interesting to note that genetic or pharmacological activation of BECN1 enhanced the anticancer activity of erastin in multiple preclinical animal tumor models. In particular, a BECN1 activator peptide enhanced BECN1-SLC7A11 complex formation and lipid peroxidation in vitro and/or in vivo. The BECN1 activator peptide has previously been reported to trigger autophagic cell death in fibroblasts and HeLa cancer cells independent of apoptosis or necroptosis [15] . We and others have recently demonstrated that ferroptosis is an autophagic cell death process [9, 10] , supporting the crosstalk between autophagy and different forms of regulated cell death in cancer therapy. Although the half-life of erastin is relatively short in vivo, it exhibits anticancer activity in multiple mouse models [26, 46] , indicating that unknown metabolites produced from erastin may mediate anticancer activity.
In summary, we define a regulatory signaling pathway mediated by BECN1 that positively controls ferroptosis through directly blocking system Xc -activity. This BECN1-dependent pathway may represent a potential target for the development of pharmacological agents that enhance or inhibit ferroptotic signaling pathways.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
To generate murine subcutaneous tumors, 5310 6 HCT116, CX-1, or HT1080 cells in 100 ml phosphate buffered saline (PBS; Thermo Fisher Scientific, AM9625) were injected subcutaneously right of the dorsal midline in athymic nude immunodeficient mice (six-to eight-week-old, female). To generate orthotopic tumors, 13 10 6 KPC cells in 10 ml PBS were surgically implanted into the pancreases of immunocompetent C57BL/6J mice (six-to eight-week-old, female) [47, 48] . All animal experiments were approved by the Institutional Animal Care and Use Committees and performed in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines (https://www.aaalac.org). Mice were health checked daily throughout the experiment and kept on a regular 12 hr light and dark cycle with normal diet in a pathogen-free barrier facility. Mice were not involved in previous procedures and test naïve.
Cell Culture
The HCT116 (CCL-247, male), PANC1 (CCL-1469, male), HT1080 (CCL-121, male), Calu- , 11095080 ) supplemented with 10% heat-inactivated fetal bovine serum (Millipore, TMS-013-B) and 1% penicillin and streptomycin (Thermo Fisher Scientific, 15070-063) at 37 C, 95% humidity, and 5% CO 2 . All cells were mycoplasma-free and authenticated using Short Tandem Repeat DNA Profiling Analysis.
METHOD DETAILS
Cell viability assay Cells were seeded into 96-well plates and incubated with the indicated treatments. Subsequently, 100 ml fresh medium was added to cells containing 10 ml Cell Counting Kit-8 (CCK-8) solutions (Dojindo Laboratories, CK04) and incubated for 2 h (37 C, 5% CO 2 ). Absorbance at 450 nm was measured using a microplate reader (CytationÔ 5 Cell Imaging Multi-Mode Reader, BioTek, USA). Propidium iodide staining was used to assay cell death.
Western blot analysis
Cells were lysed with 1X cell lysis buffer (Cell Signaling Technology, 9803) containing protease inhibitor (Sigma-Aldrich, P8340) on ice for 10 min, homogenized by passing through a 21-gauge needle, and centrifuged at 14,000 x g for 15 min at 4
C to pellet the cell debris. Protein was quantified using the BCA assay (Thermo Fisher Scientific, 23225) and 20 mg of each sample was resolved on 4%-12% Criterion XT Bis-Tris gels (Bio-Rad, 3450124) in XT MES running buffer (Bio-Rad, 1610789) and transferred to PVDF membranes (Bio-Rad, 1620233) using the Trans-BlotÒ TurboÔ Transfer Pack and System (Bio-Rad). Membranes were blocked with TBST (Cell Signaling Technology, 9997S) containing 5% skim milk for 1 h and incubated overnight at 4 C with various primary antibodies. Following 3 washes in TBST, membranes were incubated with goat anti-rabbit or anti-mouse IgG HRP secondary antibody (Cell Signaling Technology, 7074 or 7076) at room temperature for 1 h and washed. Chemiluminescence substrate was applied using SuperSignalÔ West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, 34080) or SuperSignalÔ West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, 34095) and blots were analyzed using the ChemiDocÔ Touch Imaging System (Bio-Rad).
Immunoprecipitation analysis
Cells were lysed at 4 C in ice-cold radioimmunoprecipitation assay buffer (Cell Signaling Technology, 9806) and cell lysates were cleared by brief centrifugation (13,000 g, 15 min). Concentrations of proteins in the supernatant were determined using the BCA assay. Prior to immunoprecipitation, samples containing equal amounts of proteins were pre-cleared with protein A agarose beads (Santa Cruz Biotechnology, sc-2027; 4 C, 3 h), and subsequently incubated with various irrelevant IgG or specific antibodies (5 mg/mL) in the presence of protein A agarose beads for 2 h or overnight at 4 C with gentle shaking. Following incubation, agarose beads were washed extensively with PBS and proteins were eluted by boiling in 2 3 sodium dodecyl sulfate sample buffer before sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Immunofluorescence assay
The cells were fixed with 2% PFA and incubated with primary antibodies in PBS with 1% bovine serum albumin overnight at 4 C, followed by washing and application of secondary antibodies. The secondary antibody was Alexa Fluor 488 goat anti-rabbit IgG (Thermo Fisher Scientific, R37116). The cells were counter-stained with DAPI (Thermo Fisher Scientific, H3569). After final washing, sections were protected with cover slips with anti-fading mounting medium sealed with nail polish and stored at 4 C for preservation. Immunofluorescence images were acquired using an AxioObserver Z1 Microscope with Apotome (Carl Zeiss). Quantifications of images were performed by assessing 20X high-power fields per slide and 10 fields per sample in a blinded manner.
BECN1 fragment and mutant construction
Site mutations were introduced into the BECN1 gene using the QuikChange site-directed mutagenesis kit (Agilent Technologies, 200523). The mutagenesis reactions were conducted using the primers (Table S1 ) with pcDNA4-Becn1 (Addgene, 24388; deposited by Qing Zhong) as templates. All constructs were confirmed by DNA sequence analysis.
The deletion of aa 114-128 of BECN1 was amplified by PCR using the primers (Table S1 ) with pcDNA4-Becn1 as a template. Then the PCR products were cloned into pcDNA4/3XFlag (Addgene, 24388; deposited by Qing Zhong). The deletion of aa 114-128 of the BECN1 sequence was confirmed by DNA sequence analysis.
Lentivirus production and stable transfection BECN1 was subcloned into pENTER-D-TOPO (Thermo Fisher Scientific, K240020) with an HA tag and sequenced for verification. The expression vector pLenti CMV/HA-pLenti-HA-Becn1 was generated through LR recombination between pENTR/HA-Becn1 and pLenti CMV Puro DEST (Addgene, 17452; deposited by Eric Campeau and Paul Kaufman) with Gateway LR Clonase II enzyme mix (Thermo Fisher Scientific, 11791100). Lentiviral particles were generated by co-transfecting HEK293T cells with 3rd generation
